
Oncology NEWS International
- Oncology NEWS International Vol 18 No 2
- Volume 18
- Issue 2
England eliminates prescription copay for cancer patients
Cancer patients in England will no longer have to pay prescription charges for medicines that treat their side effects, starting in April. Drugs that will be exempt include those that address pain, nausea, chronic diarrhea, fatigue, and mouth ulcers. Tamoxifen and other long-term hormone treatments are also currently subject to this charge.
Cancer patients in England will no longer have to pay prescription charges for medicines that treat their side effects, starting in April. Drugs that will be exempt include those that address pain, nausea, chronic diarrhea, fatigue, and mouth ulcers. Tamoxifen and other long-term hormone treatments are also currently subject to this charge.
Most medicines prescribed outside of hospitals by National Health Service (NHS) doctors are subject to a fixed charge of £7.10 (about $10.00) per item. Currently, patients being treated under the auspices of the NHS pay nothing for intravenous or oral chemotherapy drugs, analgesics, or antiemetics that are used during therapy sessions.
Cancer patients in England only (not the UK in general) can apply for a certificate that will exempt them from paying charges for prescription drugs for five years. They will remain eligible for free prescriptions even if they get the “all clear” before the five-year period is up. Th e exemption certificate can be renewed as many times as necessary, and it can be used when collecting any medicine prescribed by a general physician.
Up to 150,000 people already diagnosed with cancer stand to benefit from the scheme at an estimated cost to the NHS of £15 million ($21.5 million).
Government officials want to balance this loss of revenue by making greater use of generic products and by bulk-buying drugs more often.
Articles in this issue
over 16 years ago
Consortium advances multidisciplinary program for colon cancerover 16 years ago
Celator joins leukemia society for phase II trial of CPX-351over 16 years ago
Genzyme nabs FDA approval for stem cell mobilizing agentover 16 years ago
FDA launches pilot safety program for foreign drugsover 16 years ago
Radiation oncology society adopts new monikerover 16 years ago
Varian places RT units; offers storage systemover 16 years ago
Improvements in Pap screenings proposedover 16 years ago
New outlook for neuroendocrine cancerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































